Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Women's Health and Genetics/Laboratory Corporation of America, |
RCV001844703 | SCV002103926 | uncertain significance | not specified | 2022-02-17 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV002545251 | SCV003245054 | uncertain significance | Cohen syndrome | 2022-04-12 | criteria provided, single submitter | clinical testing | This sequence change replaces glycine, which is neutral and non-polar, with glutamic acid, which is acidic and polar, at codon 459 of the VPS13B protein (p.Gly459Glu). This variant is not present in population databases (gnomAD no frequency). This variant has not been reported in the literature in individuals affected with VPS13B-related conditions. ClinVar contains an entry for this variant (Variation ID: 1343686). Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Not Available"; PolyPhen-2: "Benign"; Align-GVGD: "Not Available"). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Prevention |
RCV004743589 | SCV005347634 | uncertain significance | VPS13B-related disorder | 2023-12-01 | no assertion criteria provided | clinical testing | The VPS13B c.1376G>A variant is predicted to result in the amino acid substitution p.Gly459Glu. To our knowledge, this variant has not been reported in the literature or in a large population database, indicating this variant is rare. At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. |